Allison Dorval

Role: CFO at Verve Therapeutics
Location: Suffolk County, MA, US
LinkedIn followers: 500 followers

Finance & AccountingView LinkedIn profile

About Allison Dorval

Driven financial executive with background in small and mid-cap, publicly traded and…

Experience

CFO
Verve Therapeutics
Nov 2021 — Present

Education

Bentley University - McCallum Graduate School of Business
Graduate certification in Taxation
2014 — 2016
University of Vermont
Bachelor of Science, Accounting
1993 — 1997

Skills

Financial Modeling
Sec Filings
Us Gaap
Internal Controls
Hyperion
Financial Analysis
Forecasting
U.s. Sec Filings
Management
Financial Reporting
Auditing
Finance
Revenue Recognition
Accounting
Financial Accounting
U.s. Generally Accepted Accounting Principles (Gaap)
Gaap
Sarbanes-Oxley Act
Mergers & Acquisitions
Internal Audit

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@vervetx.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Verve Therapeutics

Biotechnology Research · 160 employees · Founded 2018 · Boston, Massachusetts, United States

Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company\'s lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis.

vervetx.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Allison Dorval

Experience

CFO

Education

Bentley University - McCallum Graduate School of Business

University of Vermont

Skills

Find verified contacts for anyone on LinkedIn